Table 2.
Quality of life, abdominal pain, and inflammatory markers from T0 to T2 in the overall population of patients with UC and according to the BLM add-on therapy.
| Parameters | n | T0 | T1 | T2 | p-Value * |
|---|---|---|---|---|---|
| SIBDQ score, mean ± SD | 39 | 54 ± 8 | 52 ± 10 | 55 ± 8 | 0.104 |
| BLM group | 18 | 54 ± 9 | 56 ± 11 | 59 ± 7 | 0.023 |
| Control group | 21 | 54 ± 8 | 49 ± 8 | 51 ± 7 | 0.018 |
| VAS score, mean ± SD | 39 | 2.4 ± 1.6 | 2.6 ± 1.9 | 2.4 ± 1.8 | 0.593 |
| BLM group | 18 | 2.6 ± 1.6 | 2.4 ± 2.2 | 1.8 ± 1.8 | 0.154 |
| Control group | 21 | 2.2 ± 1.6 | 2.8 ± 1.6 | 3.0 ± 1.7 | 0.019 |
| ESR (mm/h), median (95% CI) | 39 | 12 (9–15) | 11 (8–14) | 11 (9–14) | 0.612 |
| BLM group | 18 | 16 (9–23) | 11 (8–15) | 13 (7–21) | 0.019 |
| Control group | 21 | 10 (7–14) | 12 (6–15) | 11 (8–14) | 0.464 |
| CRP (mg/dL), median (95% CI) | 39 | 0.8 (0.3–2.0) | 0.8 (0.5–3.7) | 1.0 (0.5–3.2) | 0.410 |
| BLM group | 18 | 1.7 (0.5–5.3) | 1.4 (0.3–6.7) | 1.0 (0.2–3.2) | 0.274 |
| Control group | 21 | 0.3 (0.1–1.8) | 0.7 (0.4–2.8) | 1.1 (0.5–4.0) | 0.002 |
| FC (µg/g), median (95% CI) | 39 | 233 (167–319) | 220 (132–366) | 161 (103–256) | 0.195 |
| BLM group | 18 | 209 (81–434) | 124 (57–217) | 80 (57–217) | 0.085 |
| Control group | 21 | 258 (167–375) | 364 (216–478) | 281 (157–328) | 0.051 |
* p-values were calculated by repeated-measures analysis of variance (ANOVA) for SIBDQ and VAS score, and by Friedman test for ESR, CRP and FC. Abbreviations: confidence interval (CI), male (M), female (F), fecal calprotectin (FC), confidence interval (CI), C reactive protein (CRP), erythrocyte sedimentation rate (ESR), standard deviation (SD), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and visual analogue scale (VAS).